Codiak Biosciences has withdrawn its proposed offering citing unfavourable market conditions, delaying an exit for investors including Alexandria Real Estate Equities.
The corporate-backed small molecule therapeutic developer has boosted its initial public offering from $90m to nearly $104m.
Health management app developer Livongo Health was valued at $800m as of 2018, and a range of corporate investors could exit in the offering.
UPMC and Kaiser Permanente are both in line for exits after health data platform developer Health Catalyst filed for a $100m initial public offering.
PureTech Health-backed neuropsychiatric drug developer Karuna Therapeutics raised $89.2m in an upsized offering that followed $123m in venture capital.
AIG scored an exit as genetic disease and cancer drug developer BridgeBio Pharma floated above its range while increasing the number of shares in its IPO.
Shares in Adaptive Biotechnologies, backed by Microsoft, Celgene, Illumina, LabCorp and BD Biosciences, soared more than 100% on its first day of trading.
Novel Group-backed luxury goods marketplace The RealReal will raise $300m in an initial public offering in which it will float above its range.
Morphic began trading on the Nasdaq Global Market yesterday after issuing 6 million shares priced at $15 each, providing exits to AbbVie, GSK, Novo, Pfizer, Schrödinger and ShangPharma.
Shire and Novo are in line for exits from liver disease startup Mirum Pharmaceuticals, which has filed to raise $86.3m in its IPO.